Page last updated: 2024-08-16

gatifloxacin and pyrroles

gatifloxacin has been researched along with pyrroles in 6 studies

Research

Studies (6)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	6 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Belder, R; Braunwald, E; Breen, J; Cannon, CP; McCabe, CH	1
Braunwald, E; Cannon, CP; McCabe, CH; Morrow, D; Pfeffer, MA; Ridker, PM; Rifai, N; Rose, LM	1
Braunwald, E; Cannon, CP; Morrow, DA; Ridker, PM; Rifai, N; Rose, LM	1
Clearfield, M	1
Braunwald, E; Cairns, R; Cannon, CP; Mega, JL; Morrow, DA; Murphy, S; Ridker, PM	1
Braunwald, E; Cannon, CP; Morrow, DA; Ray, KK; Rifai, N; Sabatine, MS; Shui, A	1

Trials

4 trial(s) available for gatifloxacin and pyrroles

Article	Year
C-reactive protein levels and outcomes after statin therapy. The New England journal of medicine, 2005, Jan-06, Volume: 352, Issue:1 Topics: Anticholesteremic Agents; Atorvastatin; Biomarkers; C-Reactive Protein; Cholesterol, LDL; Coronary Disease; Female; Fluoroquinolones; Gatifloxacin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Middle Aged; Myocardial Infarction; Pravastatin; Proportional Hazards Models; Pyrroles; Risk Factors; Secondary Prevention	2005
Relative efficacy of atorvastatin 80 mg and pravastatin 40 mg in achieving the dual goals of low-density lipoprotein cholesterol <70 mg/dl and C-reactive protein <2 mg/l: an analysis of the PROVE-IT TIMI-22 trial. Journal of the American College of Cardiology, 2005, May-17, Volume: 45, Issue:10 Topics: Administration, Oral; Aged; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Cholesterol, LDL; Cohort Studies; Coronary Restenosis; Dose-Response Relationship, Drug; Female; Fluoroquinolones; Follow-Up Studies; Gatifloxacin; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Myocardial Infarction; Pravastatin; Pyrroles; Secondary Prevention; Statistics as Topic; Survival Rate; Treatment Outcome	2005
Cholesterol, C-reactive protein, and cerebrovascular events following intensive and moderate statin therapy. Journal of thrombosis and thrombolysis, 2006, Volume: 22, Issue:1 Topics: Aged; Angina, Unstable; Atorvastatin; C-Reactive Protein; Cholesterol; Epidemiologic Methods; Female; Fluoroquinolones; Gatifloxacin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Pravastatin; Pyrroles; Stroke	2006
Long-term prognostic value of neopterin: a novel marker of monocyte activation in patients with acute coronary syndrome. Circulation, 2007, Jun-19, Volume: 115, Issue:24 Topics: Acute Disease; Anti-Infective Agents; Anticholesteremic Agents; Atorvastatin; Biomarkers; Coronary Artery Disease; Fluoroquinolones; Gatifloxacin; Heptanoic Acids; Humans; Monocytes; Neopterin; Pravastatin; Prognosis; Pyrroles; Risk Factors; Secondary Prevention; Survival Analysis	2007

Other Studies

2 other study(ies) available for gatifloxacin and pyrroles

Article	Year
Design of the Pravastatin or Atorvastatin Evaluation and Infection Therapy (PROVE IT)-TIMI 22 trial. The American journal of cardiology, 2002, Apr-01, Volume: 89, Issue:7 Topics: Angina, Unstable; Anti-Infective Agents; Anticholesteremic Agents; Atorvastatin; Chlamydophila Infections; Chlamydophila pneumoniae; Cholesterol, LDL; Double-Blind Method; Fluoroquinolones; Gatifloxacin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Multicenter Studies as Topic; Myocardial Infarction; Pneumonia, Bacterial; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Research Design	2002
C-reactive protein levels and outcomes after statin therapy. Current atherosclerosis reports, 2006, Volume: 8, Issue:1 Topics: Anticholesteremic Agents; Atorvastatin; Biomarkers; C-Reactive Protein; Cholesterol, LDL; Coronary Disease; Fluoroquinolones; Gatifloxacin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Multicenter Studies as Topic; Myocardial Infarction; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Recurrence; Risk Factors	2006

Article

Year

Design of the Pravastatin or Atorvastatin Evaluation and Infection Therapy (PROVE IT)-TIMI 22 trial.

The American journal of cardiology, 2002, Apr-01, Volume: 89, Issue:7

Topics: Angina, Unstable; Anti-Infective Agents; Anticholesteremic Agents; Atorvastatin; Chlamydophila Infections; Chlamydophila pneumoniae; Cholesterol, LDL; Double-Blind Method; Fluoroquinolones; Gatifloxacin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Multicenter Studies as Topic; Myocardial Infarction; Pneumonia, Bacterial; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Research Design

2002

C-reactive protein levels and outcomes after statin therapy.

Current atherosclerosis reports, 2006, Volume: 8, Issue:1

Topics: Anticholesteremic Agents; Atorvastatin; Biomarkers; C-Reactive Protein; Cholesterol, LDL; Coronary Disease; Fluoroquinolones; Gatifloxacin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Multicenter Studies as Topic; Myocardial Infarction; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Recurrence; Risk Factors

2006